James F. List - Concepedia

Author

James F. List

Bristol-Myers Squibb (United States)

Also Known As

J F List, J List, J. F. List, J. List, J.F. List, James F List, James F. List, James List

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Belgium)Dallas Diabetes Research Center Aston University

About

James F. List is an author at Bristol-Myers Squibb (United States) specializing in medicine, diabetes, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.9K
2	Diabetes	4	4	1.8K
3	Public Health	1	1	121
4	Cell Biology	1	1	155
5	Endocrinology	1	1	46

James F. List

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Clifford J. Bailey, Jorge Luiz Gross, Anne Pieters, The Lancet Metabolic SyndromeDiabetes ManagementInadequate Glycaemic ControlCardiovascular DiseaseDiabetes	2010	848
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes Hiddo J.L. Heerspink, Dick de Zeeuw, Li Wie, Diabetes Obesity and Metabolism	2013	801
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise Ele Ferrannini, Silvia Ramos, Afshin Salsali, Diabetes Care	2010	700
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes James F. List, Vincent Woo, Enrique Morales, Diabetes Care	2008	689
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Donald E. Kohan, Paola Fioretto, Weihua Tang, Kidney International ObesityMetabolic SyndromeHypertensionMean Serum CreatinineRenal Function	2013	633
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy Julio Rosenstock, Marisa L. Vico, Wei Li, Diabetes Care	2012	399
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers John Wilding, Paul Norwood, Caroline T'joen, Diabetes Care	2009	360
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial Clifford J. Bailey, J. L. Gross, Delphine Hennicken, BMC Medicine	2013	355
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Robert R. Henry, Alexander V. Murray, Marisol Herrera Marmolejo, International Journal of Clinical Practice	2012	309
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes Julio Rosenstock, Carlos A. Aguilar‐Salinas, E. Klein, Current Medical Research and Opinion	2009	286

Page 1